Floatz logo

6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)

Posttraumatic Stress Disorder

INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical ConsortiumSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Posttraumatic Stress Disorder cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Queen's University
Phase 4BBB
Sertraline
Yang I. Pachankis, PhD
Phase 4BB
Paroxetine
University of Washington
Phase 4BB
Methylphenidate
VA Office of Research and Development
Phase 4BB
Cipralex
New York State Psychiatric Institute
Phase 4BB

View all 44 →

Same molecule, other indications

6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS) is also rated in:

Alzheimer diseaseDormant
BBB
Indicative ·
73 / 100
View asset →
Lewy body dementiaDormant
BB
Indicative ·
71 / 100
View asset →
schizoaffective disorderDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →